But the intravenous treatment does not treat Alzheimers or reverse it. It could carry a price as high as $50,000-a-year per patient, according to drug analysts, including billions of dollars to the nations health tab. And, depending on how the FDA writes the label, millions of individuals could be eligible for the drug, or a minimum of for an assessment of whether they ought to take it, professionals state.
- B1617 Strain Spreading Globalwide At ‘Frightening Speed’ – Gulte
- Coronavirus in Oregon: State reports 220 new cases, 3 deaths – OregonLive